Repligen (NASDAQ:RGEN) Shares Gap Up to $208.11


Share on StockTwits

Shares of Repligen Co. (NASDAQ:RGEN) gapped up prior to trading on Tuesday . The stock had previously closed at $208.11, but opened at $214.85. Repligen shares last traded at $203.82, with a volume of 2,396 shares traded.

Several equities research analysts have weighed in on the company. Craig Hallum upped their target price on Repligen from $245.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. HC Wainwright reissued a “buy” rating and issued a $225.00 price target (up from $168.00) on shares of Repligen in a research report on Monday, April 19th. Zacks Investment Research lowered Repligen from a “strong-buy” rating to a “hold” rating and set a $200.00 target price on the stock. in a research report on Tuesday, January 5th. Finally, SVB Leerink upped their target price on Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, March 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Repligen has a consensus rating of “Buy” and an average target price of $215.20.

The firm has a fifty day moving average of $204.37 and a 200 day moving average of $198.75. The company has a debt-to-equity ratio of 0.21, a current ratio of 13.67 and a quick ratio of 12.13. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 253.07, a PEG ratio of 4.18 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 23rd. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.31 by $0.21. Repligen had a return on equity of 6.58% and a net margin of 13.40%. The business had revenue of $108.65 million during the quarter, compared to analyst estimates of $93.89 million. Research analysts anticipate that Repligen Co. will post 1.44 earnings per share for the current fiscal year.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 1,000 shares of the firm’s stock in a transaction on Wednesday, March 3rd. The stock was sold at an average price of $205.00, for a total value of $205,000.00. Following the sale, the director now directly owns 2,464 shares in the company, valued at $505,120. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP James Bylund sold 360 shares of the firm’s stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $204.25, for a total value of $73,530.00. Following the completion of the sale, the senior vice president now owns 6,324 shares in the company, valued at $1,291,677. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,382 shares of company stock valued at $9,056,388. 1.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of RGEN. Amundi Pioneer Asset Management Inc. acquired a new stake in Repligen in the first quarter valued at $2,925,000. Brinker Capital Investments LLC acquired a new position in Repligen in the 3rd quarter valued at about $221,000. Sei Investments Co. increased its position in Repligen by 66.7% in the 3rd quarter. Sei Investments Co. now owns 16,172 shares of the biotechnology company’s stock valued at $2,382,000 after acquiring an additional 6,472 shares during the period. Mercer Global Advisors Inc. ADV increased its position in Repligen by 6.4% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 3,471 shares of the biotechnology company’s stock valued at $512,000 after acquiring an additional 209 shares during the period. Finally, HM Payson & Co. acquired a new position in Repligen in the 3rd quarter valued at about $40,000. Institutional investors own 84.33% of the company’s stock.

About Repligen (NASDAQ:RGEN)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Read More: Equal Weight Rating

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.